- Home
- HTO vs GLPG Comparison
HTO vs GLPG Comparison
Compare HTO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTO
- GLPG
- Stock Information
- Founded
- HTO 1985
- GLPG 1999
- Country
- HTO United States
- GLPG Belgium
- Employees
- HTO N/A
- GLPG N/A
- Industry
- HTO Water Supply
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- HTO Utilities
- GLPG Health Care
- Exchange
- HTO Nasdaq
- GLPG Nasdaq
- Market Cap
- HTO 1.8B
- GLPG 2.1B
- IPO Year
- HTO N/A
- GLPG 2005
- Fundamental
- Price
- HTO $50.47
- GLPG $33.36
- Analyst Decision
- HTO Hold
- GLPG Sell
- Analyst Count
- HTO 1
- GLPG 4
- Target Price
- HTO $58.00
- GLPG $25.33
- AVG Volume (30 Days)
- HTO 227.0K
- GLPG 260.7K
- Earning Date
- HTO 10-27-2025
- GLPG 10-29-2025
- Dividend Yield
- HTO 3.33%
- GLPG N/A
- EPS Growth
- HTO 12.08
- GLPG N/A
- EPS
- HTO 3.05
- GLPG N/A
- Revenue
- HTO $788,737,000.00
- GLPG $323,674,692.00
- Revenue This Year
- HTO $8.17
- GLPG N/A
- Revenue Next Year
- HTO $6.15
- GLPG N/A
- P/E Ratio
- HTO $16.57
- GLPG N/A
- Revenue Growth
- HTO 12.40
- GLPG 5.43
- 52 Week Low
- HTO $44.91
- GLPG $22.36
- 52 Week High
- HTO $61.97
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- HTO 52.36
- GLPG 59.82
- Support Level
- HTO $48.80
- GLPG $30.88
- Resistance Level
- HTO $51.30
- GLPG $33.25
- Average True Range (ATR)
- HTO 0.98
- GLPG 0.75
- MACD
- HTO 0.03
- GLPG -0.02
- Stochastic Oscillator
- HTO 66.80
- GLPG 97.25
About HTO H2O America Common Stock
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.